205 related articles for article (PubMed ID: 7543271)
1. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
Février M; Boudet F; Deslandres A; Theze J
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
[TBL] [Abstract][Full Text] [Related]
3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
Boudet F; Theze J; Zouali M
Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
[TBL] [Abstract][Full Text] [Related]
5. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
6. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
[TBL] [Abstract][Full Text] [Related]
7. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
Kang CY; Hariharan K; Posner MR; Nara P
J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
[TBL] [Abstract][Full Text] [Related]
9. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
10. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
[TBL] [Abstract][Full Text] [Related]
12. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
13. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
14. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
16. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.
Tilley SA; Honnen WJ; Racho ME; Chou TC; Pinter A
AIDS Res Hum Retroviruses; 1992 Apr; 8(4):461-7. PubMed ID: 1376135
[TBL] [Abstract][Full Text] [Related]
17. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
Posner MR; Hideshima T; Cannon T; Mukherjee M; Mayer KH; Byrn RA
J Immunol; 1991 Jun; 146(12):4325-32. PubMed ID: 1710248
[TBL] [Abstract][Full Text] [Related]
18. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
Chin LT; Hinkula J; Levi M; Ohlin M; Wahren B; Borrebaeck CA
Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
[TBL] [Abstract][Full Text] [Related]
19. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
Cavacini LA; Emes CL; Power J; Duval M; Posner MR
J Immunol; 1994 Mar; 152(5):2538-45. PubMed ID: 7510748
[TBL] [Abstract][Full Text] [Related]
20. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
